Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800. The company is set for strong growth over the next 3 years. The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).
Will NSE be allowed to trade on NSE? Stock exchange may seek Sebi’s nod after listing
NSE may seek Sebi’s approval to allow its shares to trade on its own platform after its IPO, despite being formally listed only on BSE.